Direct Answer
Retatrutide (LY3437943) is an investigational GLP-1/GIP/glucagon triple-receptor agonist studied in phase 2 trials for obesity and type 2 diabetes.
Summary Table
Evidence Level
Moderate
AI Summary
Retatrutide is a synthetic, fatty-acid-modified single-chain peptide that activates the GLP-1, GIP, and glucagon receptors (Eli Lilly, LY3437943). Evidence is currently moderate: multiple phase 2 randomized controlled trials — in obesity (NEJM 2023), type 2 diabetes (Lancet 2023), and metabolic dysfunction-associated steatotic liver disease (Nature Medicine 2024) — reported dose-dependent reductions in body weight and metabolic markers, but no phase 3 outcome data are published and it is not approved by any regulator. The most commonly reported adverse events are dose-related gastrointestinal effects (nausea, vomiting, diarrhea, constipation). It is investigational and not intended for human use outside clinical trials.
Key Information
Classification
Key Takeaways
- Retatrutide is an investigational GLP-1/GIP/glucagon triple receptor agonist (Eli Lilly, LY3437943)
- Phase 2 randomized trials reported dose-dependent weight and metabolic changes; phase 3 was ongoing
- It is not approved by any regulator, and long-term safety is not established
Scientific Overview
In Plain English
Retatrutide is a lab-made peptide that acts on three gut/metabolic hormone receptors (GLP-1, GIP, and glucagon) at once. In mid-stage human trials for obesity and type 2 diabetes it was associated with dose-dependent weight loss and metabolic changes, but it has not finished late-stage trials and is not approved by regulators. The most common side effects were stomach-related (nausea, vomiting, diarrhea).
Scientific Details
Retatrutide (LY3437943) is a single-chain, lipidated peptide agonist of the GIP, GLP-1, and glucagon receptors developed by Eli Lilly. In a phase 2 obesity trial (Jastreboff et al., NEJM 2023) and a phase 2 type 2 diabetes trial (Rosenstock et al., Lancet 2023), it was associated with dose-dependent reductions in body weight and glycemic measures versus placebo; a phase 2a trial reported reductions in liver fat in MASLD (Sanyal et al., Nature Medicine 2024). Phase 3 trials were ongoing at the time of writing. The evidence base is randomized but mid-stage and industry-sponsored, without published long-term outcome or safety data.
How It Works
Retatrutide is described in research as a triple agonist of the GLP-1, GIP, and glucagon receptors. GLP-1 and GIP receptor activation is associated with reduced appetite and effects on insulin secretion, while glucagon receptor activation is hypothesized to increase energy expenditure. These mechanisms are characterized in pharmacology and mid-stage clinical studies and have not been confirmed by long-term outcome trials.
Mechanism of Action
GLP-1 receptor agonism
human
Activation of the GLP-1 receptor is associated with reduced appetite, slowed gastric emptying, and glucose-dependent insulin secretion.
GIP receptor agonism
human
Retatrutide activates the GIP receptor, a second incretin pathway involved in insulin secretion and metabolic regulation.
Glucagon receptor agonism
human
Glucagon receptor activation is hypothesized to increase energy expenditure; this is the distinguishing third target versus dual GIP/GLP-1 agonists.
Evidence Level
Human Evidence
Multiple phase 2 randomized controlled trials report dose-dependent effects: an obesity trial (NEJM 2023), a type 2 diabetes trial (Lancet 2023), and a phase 2a MASLD trial (Nature Medicine 2024). Phase 3 trials (TRIUMPH program) were ongoing.
Animal Evidence
Preclinical work characterized the triple-receptor pharmacology of the molecule.
Cell Evidence
In vitro studies characterized receptor binding and activation across the GIP, GLP-1, and glucagon receptors.
Limitations
No published phase 3 outcome data and no regulatory approval as of July 2026. Trials are industry-sponsored (Eli Lilly); long-term efficacy and safety are not established, and reported effects are in the context of ongoing treatment.
Why This Grade
Graded moderate: the peer-reviewed evidence base is randomized phase 2 trials with consistent dose-dependent findings — notably Jastreboff et al., NEJM 2023 (phase 2 obesity, DOI 10.1056/NEJMoa2301972), Rosenstock et al., Lancet 2023 (phase 2 type 2 diabetes), and Sanyal et al., Nature Medicine 2024 (phase 2a MASLD). Phase 3 results are emerging from the TRIUMPH program (including TRIUMPH-4 topline results reported December 2025) but were not yet fully peer-reviewed or regulatory-approved at the time of writing, and long-term outcome data are not established. This sits above preclinical/low-tier peptides but below the high grade reserved for approved agents with completed, published phase 3 programs.
References
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. The New England Journal of Medicine.Human Studydoi:10.1056/NEJMoa2301972 →
- Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet.Human Studydoi:10.1016/S0140-6736(23)01053-X →
- Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine.Human Studydoi:10.1038/s41591-024-03018-2 →
Alternative Names
- LY3437943
- GGG tri-agonist
- GIP/GLP-1/glucagon triple agonist
Risks & Safety
- Dose-dependent gastrointestinal adverse events (nausea, vomiting, diarrhea, constipation, abdominal discomfort) were the most commonly reported effects in trials
- Abnormal skin sensation (cutaneous hyperesthesia / dysesthesia — tingling, burning, prickling, or numbness) is a dose-related signal: reported in about 7% of retatrutide participants versus about 1% on placebo in the phase 2 obesity trial (Jastreboff et al., NEJM 2023), and, in phase 3 topline results (TRIUMPH-4, reported December 2025), as dysesthesia in about 8.8% (9 mg) and 20.9% (12 mg) versus about 0.7% on placebo; cases were generally mild and rarely led to discontinuation
- This dysesthesia signal appears distinctive to retatrutide among incretin-based drugs — it is not characteristic of GLP-1/GIP agents such as semaglutide or tirzepatide — and is attributed to its glucagon-receptor agonism; the underlying mechanism is not fully understood, and most reported cases were mild
- Mild increases in heart rate have been reported
- Class-associated risks described for incretin-based therapies include pancreatitis and gallbladder disease
- Long-term safety is not established; no completed phase 3 or approval data exist as of July 2026
- Material sold by research-chemical vendors is not quality-controlled, may be mislabeled or contaminated, and is not intended for human use
Claim Boundaries
ION BLUE is an educational research aggregator. This content summarizes published scientific literature. It is not medically reviewed, is not medical advice, and is not a recommendation to use any substance. Several peptides discussed are research chemicals or investigational drugs not approved for general human use. Consult a licensed healthcare provider. This entry summarizes mid-stage clinical research on an investigational drug and is not an assertion that retatrutide is safe or effective, nor a recommendation to obtain or use it.
This page summarizes published research and is for informational purposes only; it is not medical advice.